Advanced search
Publication Cover
Expert Opinion on Investigational Drugs Volume 18, 2009 - Issue 8
Submit an article Journal homepage
4,301
Views
370
CrossRef citations to date
0
Altmetric
Reviews

Glioblastoma multiforme: a review of where we have been and where we are going

Cory Adamson Duke Medical Center, MSRB 1 Box 2624, Durham, NC 27712, USA +1 919 698 3152; +1 919 684 5483; [email protected]; Neurosurgery Section, Durham VA Medical Center, Durham, NC, USA
, MD PhD MPH MHSc,
Okezie O Kanu Lagos University Teaching Hospital, Lagos, Nigeria
, MD,
Ankit I Mehta Duke Medical Center, MSRB 1 Box 2624, Durham, NC 27712, USA +1 919 698 3152; +1 919 684 5483; [email protected]
, MD,
Chunhui Di Duke Medical Center, MSRB 1 Box 2624, Durham, NC 27712, USA +1 919 698 3152; +1 919 684 5483; [email protected]
, BS,
Ningjing Lin Peking University School of Oncology, Beijing Cancer Hospital, Department of Oncology, Beijing, China
, MD,
Austin K Mattox Duke Medical Center, MSRB 1 Box 2624, Durham, NC 27712, USA +1 919 698 3152; +1 919 684 5483; [email protected]
, BS &
Darell D Bigner Duke Medical Center, MSRB 1 Box 2624, Durham, NC 27712, USA +1 919 698 3152; +1 919 684 5483; [email protected]
, MD PhD show all
Pages 1061-1083 | Published online: 26 Jun 2009

Bibliography

  • CBTRUS. Statistical report: primary brain tumors in the United States, 2000-2004. Chicago: Central Brain Tumor Registry of the United States, 2008
  • Yan H, Parsons DW, McLendon R, et al. IDH1 and IDH2 mutations in gliomas. N Engl J Med 2009;360(8):765-73
  • Parsons DW, Jones S, Zhang X, et al. An integrated genomic analysis of human glioblastoma multiforme. Science 2008;321(5897):1807-12
  • Ohgaki H, Dessen P, Jourde B, et al. Genetic pathways to glioblastoma: a population-based study. Cancer Res 2004;64(19):6892-9
  • Ohgaki H. Genetic pathways to glioblastomas. Neuropathology 2005;25(1):1-7
  • Godard S, Getz G, Delorenzi M, et al. Classification of human astrocytic gliomas on the basis of gene expression: a correlated group of genes with angiogenic activity emerges as a strong predictor of subtypes. Cancer Res 2003;63(20):6613-25
  • Xie D, Zeng YX, Wang HJ, et al. Expression of cytoplasmic and nuclear Survivin in primary and secondary human glioblastoma. Br J Cancer 2006;94(1):108-14
  • Schrock E, du Manoir S, Veldman T, et al. Multicolor spectral karyotyping of human chromosomes. Science 1996;273(5274):494-7
  • Watanabe K, Tachibana O, Sata K, et al. Overexpression of the EGF receptor and p53 mutations are mutually exclusive in the evolution of primary and secondary glioblastomas. Brain Pathol 1996;6(3):217-23; discussion 23-4
  • Karcher S, Steiner HH, Ahmadi R, et al. Different angiogenic phenotypes in primary and secondary glioblastomas. Int J Cancer 2006;118(9):2182-9
  • Louis DN, von Deimling A, Chung RY, et al. Comparative study of p53 gene and protein alterations in human astrocytic tumors. J Neuropathol Exp Neurol 1993;52(1):31-8
  • Dohrmann GJ, Farwell JR, Flannery JT. Glioblastoma multiforme in children. J Neurosurg 1976;44(4):442-8
  • SEER, SEER*Stat Release 6.3.5. 2007. Available at: http://seer.cancer.gov/seerstat/software
  • Capocaccia R, Gatta G, Roazzi P, et al. EUROCARE Working Group. The EUROCARE-3 database: methodology of data collection, standardisation, quality control and statistical analysis. Ann Oncol 2003;14(Suppl 5):v14-27
  • Stewart LA. Chemotherapy in adult high-grade glioma: a systematic review and meta-analysis of individual patient data from 12 randomised trials. Lancet 2002;359(9311):1011-8
  • Hess KR, Broglio KR, Bondy ML. Adult glioma incidence trends in the United States, 1977-2000. Cancer 2004;101(10):2293-9
  • Christensen HC, Kosteljanetz M, Johansen C. Incidences of gliomas and meningiomas in Denmark, 1943 to 1997. Neurosurgery 2003;52(6):1327-33; discussion 1333-4
  • Wrensch M, Lee M, Miike R, et al. Familial and personal medical history of cancer and nervous system conditions among adults with glioma and controls. Am J Epidemiol 1997;145(7):581-93
  • Wrensch M, Minn Y, Chew T, et al. Epidemiology of primary brain tumors: current concepts and review of the literature. Neuro Oncol 2002;4(4):278-99
  • Hodges LC, Smith JL, Garrett A, Tate S. Prevalence of glioblastoma multiforme in subjects with prior therapeutic radiation. J Neurosci Nurs 1992;24(2):79-83
  • Nichols KE, Malkin D, Garber JE, et al. Germ-line p53 mutations predispose to a wide spectrum of early-onset cancers. Cancer Epidemiol Biomarkers Prev 2001;10(2):83-7
  • Fisher JL, Schwartzbaum JA, Wrensch M, Wiemels JL. Epidemiology of brain tumors. Neurol Clin 2007;25(4):867-90, vii
  • Demers PA, Vaughan TL, Schommer RR. Occupation, socioeconomic status, and brain tumor mortality: a death certificate-based case-control study. J Occup Med 1991;33(9):1001-6
  • Hardell L, Carlberg M, Soderqvist F, et al. Long-term use of cellular phones and brain tumours: increased risk associated with use for > or = 10 years. Occup Environ Med 2007;64(9):626-32
  • Shinojima N, Tada K, Shiraishi S, et al. Prognostic value of epidermal growth factor receptor in patients with glioblastoma multiforme. Cancer Res 2003;63(20):6962-70
  • McLendon RE, Robinson JS Jr, Chambers DB, et al. The glioblastoma multiforme in Georgia, 1977-1981. Cancer 1985;56(4):894-7
  • Parkin DM, Muir CS. Cancer incidence in five continents. Comparability and quality of data. IARC Sci Publ 1992;120:45-173
  • Krex D, Klink B, Hartmann C, et al. Long-term survival with glioblastoma multiforme. Brain 2007;130(Pt 10):2596-606
  • Curran WJ Jr, Scott CB, Horton J, et al. Recursive partitioning analysis of prognostic factors in three Radiation Therapy Oncology Group malignant glioma trials. J Natl Cancer Inst 1993;85(9):704-10
  • Mirimanoff RO, Gorlia T, Mason W, et al. Radiotherapy and temozolomide for newly diagnosed glioblastoma: recursive partitioning analysis of the EORTC 26981/22981-NCIC CE3 phase III randomized trial. J Clin Oncol 2006;24(16):2563-9
  • Kleihues P, Cavenee WK. WHO classification of tumors. Pathology and genetics of tumors of the nervous system. 2000, Lyon: IARCpress
  • Reardon DA, Rich JN, Friedman HS, Bigner DD. Recent advances in the treatment of malignant astrocytoma. J Clin Oncol 2006;24(8):1253-65
  • Burger PC, Vogel FS, Green SB, Strike TA. Glioblastoma multiforme and anaplastic astrocytoma. Pathologic criteria and prognostic implications. Cancer 1985;56(5):1106-11
  • The Cancer Genome Atlas Research Network. Comprehensive genomic characterization defines human glioblastoma genes and core pathways. Nature 2008;455(7216):1061-8
  • Kim DH, Mohapatra G, Bollen A, et al. Chromosomal abnormalities in glioblastoma multiforme tumors and glioma cell lines detected by comparative genomic hybridization. Int J Cancer 1995;60(6):812-9
  • Mohapatra G, Bollen AW, Kim DH, et al. Genetic analysis of glioblastoma multiforme provides evidence for subgroups within the grade. Genes Chromosomes Cancer 1998;21(3):195-206
  • Nishizaki T, Ozaki S, Harada K, et al. Investigation of genetic alterations associated with the grade of astrocytic tumor by comparative genomic hybridization. Genes Chromosomes Cancer 1998;21(4):340-6
  • von Deimling A, Fimmers R, Schmidt MC, et al. Comprehensive allelotype and genetic anaysis of 466 human nervous system tumors. J Neuropathol Exp Neurol 2000;59(6):544-58
  • Collins VP. Brain tumours: classification and genes. J Neurol Neurosurg Psychiatry 2004;75(Suppl 2):ii2-11
  • Vranova V, Necesalova E, Kuglik P, et al. Screening of genomic imbalances in glioblastoma multiforme using high-resolution comparative genomic hybridization. Oncol Rep 2007;17(2):457-64
  • Rasheed BK, McLendon RE, Friedman HS, et al. Chromosome 10 deletion mapping in human gliomas: a common deletion region in 10q25. Oncogene 1995;10(11):2243-6
  • Hui AB, Lo KW, Yin XL, et al. Detection of multiple gene amplifications in glioblastoma multiforme using array-based comparative genomic hybridization. Lab Invest 2001;81(5):717-23
  • Ruano Y, Mollejo M, Ribalta T, et al. Identification of novel candidate target genes in amplicons of Glioblastoma multiforme tumors detected by expression and CGH microarray profiling. Mol Cancer 2006;5(article 39):1-12 [online journal]
  • Wong AJ, Bigner SH, Bigner DD, et al. Increased expression of the epidermal growth factor receptor gene in malignant gliomas is invariably associated with gene amplification. Proc Natl Acad Sci USA 1987;84(19):6899-903
  • Loeb LA. Mutator phenotype may be required for multistage carcinogenesis. Cancer Res 1991;51(12):3075-9
  • Hoeijmakers JH. Genome maintenance mechanisms for preventing cancer. Nature 2001;411(6835):366-74
  • Silber JR, Bobola MS, Ghatan S, et al. O6-methylguanine-DNA methyltransferase activity in adult gliomas: relation to patient and tumor characteristics. Cancer Res 1998;58(5):1068-73
  • Belanich M, Pastor M, Randall T, et al. Retrospective study of the correlation between the DNA repair protein alkyltransferase and survival of brain tumor patients treated with carmustine. Cancer Res 1996;56(4):783-8
  • Watts GS, Pieper RO, Costello JF, et al. Methylation of discrete regions of the O6-methylguanine DNA methyltransferase (MGMT) CpG island is associated with heterochromatinization of the MGMT transcription start site and silencing of the gene. Mol Cell Biol 1997;17(9):5612-9
  • Nakamura M, Watanabe T, Yonekawa Y, et al. Promoter methylation of the DNA repair gene MGMT in astrocytomas is frequently associated with G:C –> A:T mutations of the TP53 tumor suppressor gene. Carcinogenesis 2001;22(10):1715-9
  • Rasheed BK, Wiltshire RN, Bigner SH, Bigner DD. Molecular pathogenesis of malignant gliomas. Curr Opin Oncol 1999;11(3):162-7
  • Wikstrand CJ, Reist CJ, Archer GE, et al. The class III variant of the epidermal growth factor receptor (EGFRvIII): characterization and utilization as an immunotherapeutic target. J Neurovirol 1998;4(2):148-58
  • Sugawa N, Ekstrand AJ, James CD, Collins VP. Identical splicing of aberrant epidermal growth factor receptor transcripts from amplified rearranged genes in human glioblastomas. Proc Natl Acad Sci USA 1990;87(21):8602-6
  • Schwechheimer K, Huang S, Cavenee WK. EGFR gene amplification–rearrangement in human glioblastomas. Int J Cancer 1995;62(2):145-8
  • Nagane M, Levitzki A, Gazit A, et al. Drug resistance of human glioblastoma cells conferred by a tumor-specific mutant epidermal growth factor receptor through modulation of Bcl-XL and caspase-3-like proteases. Proc Natl Acad Sci USA 1998;95(10):5724-9
  • Hermanson M, Funa K, Hartman M, et al. Platelet-derived growth factor and its receptors in human glioma tissue: expression of messenger RNA and protein suggests the presence of autocrine and paracrine loops. Cancer Res 1992;52(11):3213-9
  • Libermann TA, Nusbaum HR, Razon N, et al. Amplification, enhanced expression and possible rearrangement of EGF receptor gene in primary human brain tumours of glial origin. Nature 1985;313(5998):144-7
  • Ronnstrand L, Heldin CH. Mechanisms of platelet-derived growth factor-induced chemotaxis. Int J Cancer 2001;91(6):757-62
  • Guha A, Feldkamp MM, Lau N, Boss G, Pawson A. Proliferation of human malignant astrocytomas is dependent on Ras activation. Oncogene 1997;15(23):2755-65
  • Fulci G, Labuhn M, Maier D, et al. p53 gene mutation and ink4a-arf deletion appear to be two mutually exclusive events in human glioblastoma. Oncogene 2000;19(33):3816-22
  • He J, Olson JJ, James CD. Lack of p16INK4 or retinoblastoma protein (pRb), or amplification-associated overexpression of cdk4 is observed in distinct subsets of malignant glial tumors and cell lines. Cancer Res 1995;55(21):4833-6
  • Ishii N, Maier D, Merlo A, et al. Frequent co-alterations of TP53, p16/CDKN2A, p14ARF, PTEN tumor suppressor genes in human glioma cell lines. Brain Pathol 1999;9(3):469-79
  • Labuhn M, Jones G, Speel EJ, et al. Quantitative real-time PCR does not show selective targeting of p14(ARF) but concomitant inactivation of both p16(INK4A) and p14(ARF) in 105 human primary gliomas. Oncogene 2001;20(9):1103-9
  • Preusser M, Haberler C, Hainfellner JA. Malignant glioma: neuropathology and neurobiology. Wien Med Wochenschr 2006;156(11-12):332-7
  • Sherr CJ, Roberts JM. CDK inhibitors: positive and negative regulators of G1-phase progression. Genes Dev 1999;13(12):1501-12
  • Li J, Yen C, Liaw D, et al. PTEN, a putative protein tyrosine phosphatase gene mutated in human brain, breast, and prostate cancer. Science 1997;275(5308):1943-7
  • Steck PA, Pershouse MA, Jasser SA, et al. Identification of a candidate tumour suppressor gene, MMAC1, at chromosome 10q23.3 that is mutated in multiple advanced cancers. Nat Genet 1997;15(4):356-62
  • Maehama T, Dixon JE. The tumor suppressor, PTEN/MMAC1, dephosphorylates the lipid second messenger, phosphatidylinositol 3,4,5-trisphosphate. J Biol Chem 1998;273(22):13375-8
  • Maehama T, Dixon JE. PTEN: a tumour suppressor that functions as a phospholipid phosphatase. Trends Cell Biol 1999;9(4):125-8
  • Maier D, Jones G, Li X, et al. The PTEN lipid phosphatase domain is not required to inhibit invasion of glioma cells. Cancer Res 1999;59(21):5479-82
  • Kurpad SN, Zhao XG, Wikstrand CJ, et al. Tumor antigens in astrocytic gliomas. Glia 1995;15(3):244-56
  • Chi DD, Merchant RE, Rand R, et al. Molecular detection of tumor-associated antigens shared by human cutaneous melanomas and gliomas. Am J Pathol 1997;150(6):2143-52
  • Brooks WH, Netsky MG, Normansell DE, Horwitz DA. Depressed cell-mediated immunity in patients with primary intracranial tumors. Characterization of a humoral immunosuppressive factor. J Exp Med 1972;136(6):1631-47
  • Brooks WH, Caldwell HD, Mortara RH. Immune responses in patients with gliomas. Surg Neurol 1974;2(6):419-23
  • Brem H, Mahaley MS Jr. Vick NA, et al. Interstitial chemotherapy with drug polymer implants for the treatment of recurrent gliomas. J Neurosurg 1991;74(3):441-6
  • Menzies CB, Gunar M, Thomas DG, Behan PO. Impaired thymus-derived lymphocyte function in patients with malignant brain tumour. Clin Neurol Neurosurg 1980;82(3):157-68
  • Brooks WH, Roszman TL, Mahaley MS, Woosley RE. Immunobiology of primary intracranial tumours. II. Analysis of lymphocyte subpopulations in patients with primary brain tumours. Clin Exp Immunol 1977;29(1):61-6
  • Brooks WH, Roszman TL, Rogers AS. Impairment of rosette-forming T lymphocytes in patients with primary intracranial tumors. Cancer 1976;37(4):1869-73
  • Braun DP, Penn RD, Flannery AM, Harris JE. Immunoregulatory cell function in peripheral blood leukocytes of patients with intracranial gliomas. Neurosurgery 1982;10(2):203-9
  • Elliott LH, Brooks WH, Roszman TL. Inability of mitogen-activated lymphocytes obtained from patients with malignant primary intracranial tumors to express high affinity interleukin 2 receptors. J Clin Invest 1990;86(1):80-6
  • Miescher S, Whiteside TL, Carrel S, von Fliedner V. Functional properties of tumor-infiltrating and blood lymphocytes in patients with solid tumors: effects of tumor cells and their supernatants on proliferative responses of lymphocytes. J Immunol 1986;136(5):1899-907
  • Roszman TL, Brooks WH, Elliott LH. Immunobiology of primary intracranial tumors. VI. Suppressor cell function and lectin-binding lymphocyte subpopulations in patients with cerebral tumors. Cancer 1982;50(7):1273-9
  • Roszman TL, Elliott LH, Brooks WH. Proliferative potential of T-cell lymphocytes from gliomas. J Neurosurg 1992;77(5):820-1
  • Roszman TL, Brooks WH. Immunobiology of primary intracranial tumours. III. Demonstration of a qualitative lymphocyte abnormality in patients with primary brain tumours. Clin Exp Immunol 1980;39(2):395-402
  • Zou JP, Morford LA, Chougnet C, et al. Human glioma-induced immunosuppression involves soluble factor(s) that alters monocyte cytokine profile and surface markers. J Immunol 1999;162(8):4882-92
  • Keime-Guibert F, Chinot O, Taillandier L, et al. Radiotherapy for glioblastoma in the elderly. N Engl J Med 2007;356(15):1527-35
  • Westphal M, Ram Z, Riddle V, Hilt D, Bortey E, Exec Comm Gliadel Study Group. Gliadel wafer in initial surgery for malignant glioma: long-term follow-up of a multicenter controlled trial. Acta Neurochir (Wien) 2006;148(3):269-75; discussion 275
  • Westphal M, Hilt DC, Bortey E, et al. A phase 3 trial of local chemotherapy with biodegradable carmustine (BCNU) wafers (Gliadel wafers) in patients with primary malignant glioma. Neurooncol 2003;5(2):79-88
  • Chang CH, Horton J, Schoenfeld D, et al. Comparison of postoperative radiotherapy and combined postoperative radiotherapy and chemotherapy in the multidisciplinary management of malignant gliomas. A joint Radiation Therapy Oncology Group and Eastern Cooperative Oncology Group study. Cancer 1983;52(6):997-1007
  • Simpson JR, Horton J, Scott C, et al. Influence of location and extent of surgical resection on survival of patients with glioblastoma multiforme: results of three consecutive Radiation Therapy Oncology Group (RTOG) clinical trials. Int J Radiat Oncol Biol Phys 1993;26(2):239-44
  • Wood JR, Green SB, Shapiro WR. The prognostic importance of tumor size in malignant gliomas: a computed tomographic scan study by the Brain Tumor Cooperative Group. J Clin Oncol 1988;6(2):338-43
  • Lacroix M, Abi-Said D, Fourney DR, et al. A multivariate analysis of 416 patients with glioblastoma multiforme: prognosis, extent of resection, and survival. J Neurosurg 2001;95(2):190-8
  • Stummer W, Reulen HJ, Meinel T, et al. Extent of resection and survival in glioblastoma multiforme: identification of and adjustment for bias. Neurosurgery 2008;62(3):564-76; discussion 564-76
  • Long DM, Gordon T, Bowman H, et al. Outcome and cost of craniotomy performed to treat tumors in regional academic referral centers. Neurosurgery 2003;52(5):1056-63; discussion 1063-5
  • Kristiansen K, Hagen S, Kollevold T, et al. Combined modality therapy of operated astrocytomas grade III and IV. Confirmation of the value of postoperative irradiation and lack of potentiation of bleomycin on survival time: a prospective multicenter trial of the Scandinavian Glioblastoma Study Group. Cancer 1981;47(4):649-52
  • Walker MD, Alexander E Jr, Hunt WE, et al. Evaluation of BCNU and/or radiotherapy in the treatment of anaplastic gliomas. A cooperative clinical trial. J Neurosurg 1978;49(3):333-43
  • Fine HA, Dear KB, Loeffler JS, et al. Meta-analysis of radiation therapy with and without adjuvant chemotherapy for malignant gliomas in adults. Cancer 1993;71(8):2585-97
  • Brem H, Piantadosi S, Burger PC, et al. Placebo-controlled trial of safety and efficacy of intraoperative controlled delivery by biodegradable polymers of chemotherapy for recurrent gliomas. The Polymer-brain Tumor Treatment Group. Lancet 1995;345(8956):1008-12
  • Stupp R, Mason WP, van den Bent MJ, et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med 2005;352(10):987-96
  • Hegi ME, Diserens AC, Gorlia T, et al. MGMT gene silencing and benefit from temozolomide in glioblastoma. N Engl J Med 2005;352:997-1003
  • Sathornsumetee S, Rich JN, Reardon DA. Diagnosis and treatment of high-grade astrocytoma. Neurol Clin 2007;25(4):1111-39, x
  • Furnari FB, Fenton T, Bachoo RM, et al. Malignant astrocytic glioma: genetics, biology, and paths to treatment. Genes Dev 2007;21(21):2683-710
  • Chi AS, Wen PY. Inhibiting kinases in malignant gliomas. Expert Opin Ther Targets 2007;11(4):473-96
  • Sathornsumetee S, Reardon DA, Desjardins A, et al. Molecularly targeted therapy for malignant glioma. Cancer 2007;110(1):13-24
  • Wen PY, Kesari S. Malignant gliomas in adults. N Engl J Med 2008;359(5):492-507
  • Stommel JM, Kimmelman AC, Ying H, et al. Coactivation of receptor tyrosine kinases affects the response of tumor cells to targeted therapies. Science 2007;318(5848):287-90
  • Vredenburgh JJ, Desjardins A, Herndon JE II, et al. Phase II trial of bevacizumab and irinotecan in recurrent malignant glioma. Clin Cancer Res 2007;13(4):1253-9
  • Desjardins A, Reardon DA, Herndon JE II, et al. Bevacizumab plus irinotecan in recurrent WHO grade 3 malignant gliomas. Clin Cancer Res 2008;14(21):7068-73
  • Sathornsumetee S, Cao Y, Marcello JE, et al. Tumor angiogenic and hypoxic profiles predict radiographic response and survival in malignant astrocytoma patients treated with bevacizumab and irinotecan. J Clin Oncol 2008;26(2):271-8
  • Vredenburgh JJ, et al. Bevacizumab plus irinotecan in recurrent glioblastoma multiforme. J Clin Oncol 2007;25(30):4722-9
  • Parney IF, Hao C, Petruk KC. Glioma immunology and immunotherapy. Neurosurgery 2000;46(4):778-91; discussion 791-2
  • Wallace MR, et al. Type 1 neurofibromatosis gene: identification of a large transcript disrupted in three NF1 patients. Science 1990;249(4965):181-6
  • Stummer W, et al. Fluorescence-guided surgery with 5-aminolevulinic acid for resection of malignant glioma: a randomised controlled multicentre phase III trial. Lancet Oncol 2006;7(5):392-401
  • Faury D, et al. Molecular profiling identifies prognostic subgroups of pediatric glioblastoma and shows increased YB-1 expression in tumors. J Clin Oncol 2007;25(10):1196-208
  • Walker MD, Strike TA, Sheline GE. An analysis of dose-effect relationship in the radiotherapy of malignant gliomas. Int J Radiat Oncol Biol Phys 1979;5(10):1725-31
  • Chin HW, Young AB, Maruyama Y. Survival response of malignant gliomas to radiotherapy with or without BCNU or methyl-CCNU chemotherapy at the University of Kentucky Medical Center. Cancer Treat Rep 1981;65(1-2):45-51
  • Walker MD, et al. Evaluation of mithramycin in the treatment of anaplastic gliomas. J Neurosurg 1976;44(6):655-67
  • Reagan TJ, et al. Controlled study of CCNU and radiation therapy in malignant astrocytoma. J Neurosurg 1976;44(2):186-90
  • Weir B, et al. Radiotherapy and CCNU in the treatment of high-grade supratentorial astrocytomas. J Neurosurg 1976;45(2):129-34
  • Solero CL, et al. Controlled study with BCNU vs. CCNU as adjuvant chemotherapy following surgery plus radiotherapy for glioblastoma multiforme. Cancer Clin Trials 1979;2(1):43-8
  • Walker MD, Green SB, Byar DP, et al. Randomized comparisons of radiotherapy and nitrosoureas for the treatment of malignant glioma after surgery. N Engl J Med 1980;303(23):1323-9
  • European Organisation for Research and Treatment of Cancer. Effect of CCNU on survival rate of objective remission and duration of free interval in patients with malignant brain glioma–final evaluation. E.O.R.T.C. Brain Tumor Group. Eur J Cancer 1978;14(8):851-6
  • Hatlevoll R, et al. Combined modality treatment of operated astrocytomas grade 3 and 4. A prospective and randomized study of misonidazole and radiotherapy with two different radiation schedules and subsequent CCNU chemotherapy. Stage II of a prospective multicenter trial of the Scandinavian Glioblastoma Study Group. Cancer 1985;56(1):41-7
  • Urtasun R, et al. Radiation and high-dose metronidazole in supratentorial glioblastomas. N Engl J Med 1976;294(25):1364-7
  • Eyre HJ, et al. Randomized comparisons of radiotherapy and CCNU versus radiotherapy, CCNU plus procarbazine for the treatment of malignant gliomas following surgery. A Southwest Oncology Group Report. J Neurooncol 1983;1(3):171-7
  • Nelson DF, et al. Combined modality approach to treatment of malignant gliomas–re-evaluation of RTOG 7401/ECOG 1374 with long-term follow-up: a joint study of the Radiation Therapy Oncology Group and the Eastern Cooperative Oncology Group. NCI Monogr 1988;6:279-84
  • Bleehen NM, et al. A randomized study of misonidazole and radiotherapy for grade 3 and 4 cerebral astrocytoma. Br J Cancer 1981;43(4):436-42
  • Urtasun R, et al. Radiation and nitromidazoles in supratentorial high grade gliomas: a second clinical trial. Br J Cancer 1982;46(1):101-8
  • Green SB, et al. Comparisons of carmustine, procarbazine, and high-dose methylprednisolone as additions to surgery and radiotherapy for the treatment of malignant glioma. Cancer Treat Rep 1983;67(2):121-32
  • Payne DG, et al. Malignant astrocytoma: hyperfractionated and standard radiotherapy with chemotherapy in a randomized prospective clinical trial. Cancer 1982;50(11):2301-6
  • Griffin TW, et al. Fast neutron radiation therapy for glioblastoma multiforme. Results of an RTOG study. Am J Clin Oncol 1983;6(6):661-7
  • Eyre HJ, et al. Randomized comparisons of radiotherapy and carmustine versus procarbazine versus dacarbazine for the treatment of malignant gliomas following surgery: a Southwest Oncology Group Study. Cancer Treat Rep, 1986;70(9):1085-90
  • Afra D, et al. Combined radiotherapy and chemotherapy with dibromodulcitol and CCNU in the postoperative treatment of malignant gliomas. J Neurosurg 1983;59(1):106-10
  • Shin KH, Muller PJ, Geggie PH. Superfractionation radiation therapy in the treatment of malignant astrocytoma. Cancer 1983;52(11):2040-3
  • Deutsch M, et al. Results of a randomized trial comparing BCNU plus radiotherapy, streptozotocin plus radiotherapy, BCNU plus hyperfractionated radiotherapy, and BCNU following misonidazole plus radiotherapy in the postoperative treatment of malignant glioma. Int J Radiat Oncol Biol Phys 1989;16(6):1389-96
  • Medical Research Council (UK). A study of the effect of misonidazole in conjunction with radiotherapy for the treatment of grades 3 and 4 astrocytomas. A report from the MRC Working Party on misonidazole in gliomas. Br J Radiol 1983;56(669):673-82
  • Nelson DF, et al. A randomized comparison of misonidazole sensitized radiotherapy plus BCNU and radiotherapy plus BCNU for treatment of malignant glioma after surgery: final report of an RTOG study. Int J Radiat Oncol Biol Phys 1986;12(10):1793-800
  • Takakura K, et al. Effects of ACNU and radiotherapy on malignant glioma. J Neurosurg 1986;64(1):53-7
  • Shapiro WR, et al. Randomized trial of three chemotherapy regimens and two radiotherapy regimens and two radiotherapy regimens in postoperative treatment of malignant glioma. Brain Tumor Cooperative Group Trial 8001. J Neurosurg 1989;71(1):1-9
  • Elliott TE, et al. Randomized trial of radiation therapy (RT) plus dibromodulcitol (DBD) versus RT plus BCNU in high grade astrocytoma. J Neurooncol 1997;33(3):239-50
  • EORTC Brain Tumor Group. Evaluation of CCNU, VM-26 plus CCNU, and procarbazine in supratentorial brain gliomas. Final evaluation of a randomized study. European Organization for Research on Treatment of Cancer (EORTC) Brain Tumor Group. J Neurosurg 1981;55(1):27-31
  • Mahaley MS Jr, et al. Randomized phase III trial of single versus multiple chemotherapeutic treatment following surgery and during radiotherapy for patients with anaplastic gliomas. Surg Neurol 1987;27(5):430-2
  • Ludgate CM, et al. Superfractionated radiotherapy in grade III, IV intracranial gliomas. Int J Radiat Oncol Biol Phys 1988;15(5):1091-5
  • Sandberg-Wollheim M, et al. A randomized study of chemotherapy with procarbazine, vincristine, and lomustine with and without radiation therapy for astrocytoma grades 3 and/or 4. Cancer 1991;68(1):22-9
  • Levin VA, et al. Superiority of post-radiotherapy adjuvant chemotherapy with CCNU, procarbazine, and vincristine (PCV) over BCNU for anaplastic gliomas: NCOG 6G61 final report. Int J Radiat Oncol Biol Phys 1990;18(2):321-4
  • Bleehen NM, Stenning SP. A Medical Research Council trial of two radiotherapy doses in the treatment of grades 3 and 4 astrocytoma. The Medical Research Council Brain Tumour Working Party. Br J Cancer 1991;64(4):769-74
  • Shapiro WR, et al. A randomized comparison of intra-arterial versus intravenous BCNU, with or without intravenous 5-fluorouracil, for newly diagnosed patients with malignant glioma. J Neurosurg 1992;76(5):772-81
  • Dinapoli RP, et al. Phase III comparative evaluation of PCNU and carmustine combined with radiation therapy for high-grade glioma. J Clin Oncol 1993;11(7):1316-21
  • Medical Research Council Brain Tumor Working Party. Randomized trial of procarbazine, lomustine, and vincristine in the adjuvant treatment of high-grade astrocytoma: a Medical Research Council trial. J Clin Oncol 2001;19(2):509-18
  • Selker RG, et al. The Brain Tumor Cooperative Group NIH Trial 87-01: a randomized comparison of surgery, external radiotherapy, and carmustine versus surgery, interstitial radiotherapy boost, external radiation therapy, and carmustine. Neurosurgery 2002;51(2):343-55; discussion 355-7
  • Trojanowski T, et al. Postoperative radiotherapy and radiotherapy combined with CCNU chemotherapy for treatment of brain gliomas. J Neurooncol 1988;6(3):285-91
  • Pickles T, et al. Pion radiation for high grade astrocytoma: results of a randomized study. Int J Radiat Oncol Biol Phys 1997;37(3):491-7
  • Hildebrand J, et al. Adjuvant therapy with dibromodulcitol and BCNU increases survival of adults with malignant gliomas. EORTC Brain Tumor Group. Neurology 1994;44(8):1479-83
  • Valtonen S, et al. Interstitial chemotherapy with carmustine-loaded polymers for high-grade gliomas: a randomized double-blind study. Neurosurgery 1997;41(1):44-8; discussion 48-9
  • Weller M, et al. Neuro-Oncology Working Group 01 trial of nimustine plus teniposide versus nimustine plus cytarabine chemotherapy in addition to involved-field radiotherapy in the first-line treatment of malignant glioma. J Clin Oncol 2003;21(17):3276-84
  • Buckner JC, et al. Phase III trial of carmustine and cisplatin compared with carmustine alone and standard radiation therapy or accelerated radiation therapy in patients with glioblastoma multiforme: North Central Cancer Treatment Group 93-72-52 and Southwest Oncology Group 9503 Trials. J Clin Oncol 2006;24(24):3871-9
  • Levin VA, et al. Randomized, double-blind, placebo-controlled trial of marimastat in glioblastoma multiforme patients following surgery and irradiation. J Neurooncol 2006;78(3):295-302
  • Rainov NG. A phase III clinical evaluation of herpes simplex virus type 1 thymidine kinase and ganciclovir gene therapy as an adjuvant to surgical resection and radiation in adults with previously untreated glioblastoma multiforme. Hum Gene Ther 2000;11(17):2389-401
  • Grossman SA, et al. Phase III study comparing three cycles of infusional carmustine and cisplatin followed by radiation therapy with radiation therapy and concurrent carmustine in patients with newly diagnosed supratentorial glioblastoma multiforme: Eastern Cooperative Oncology Group Trial 2394. J Clin Oncol 2003;21(8):1485-91
  • Willems PW, et al. Effectiveness of neuronavigation in resecting solitary intracerebral contrast-enhancing tumors: a randomized controlled trial. J Neurosurg 2006;104(3):360-8
  • Combs SE, et al. Radiochemotherapy in patients with primary glioblastoma comparing two temozolomide dose regimens. Int J Radiat Oncol Biol Phys 2008;71(4):999-1005
  • Sotelo J, Briceno E, Lopez-Gonzalez MA. Adding chloroquine to conventional treatment for glioblastoma multiforme: a randomized, double-blind, placebo-controlled trial. Ann Intern Med 2006;144(5):337-43
  • Wu JS, et al. Clinical evaluation and follow-up outcome of diffusion tensor imaging-based functional neuronavigation: a prospective, controlled study in patients with gliomas involving pyramidal tracts. Neurosurgery 2007;61(5):935-48; discussion 948-9
  • Imbesi F, et al. A randomized phase III study: comparison between intravenous and intraarterial ACNU administration in newly diagnosed primary glioblastomas. Anticancer Res 2006;26(1B):553-8
  • Henriksson R, et al. High-grade astrocytoma treated concomitantly with estramustine and radiotherapy. J Neurooncol 2006;78(3):321-6
  • Sampson JH, et al. Comparison of intratumoral bolus injection and convection-enhanced delivery of radiolabeled antitenascin monoclonal antibodies. Neurosurg Focus 2006;20(4):E14
  • Wygoda Z, et al. Use of monoclonal anti-EGFR antibody in the radioimmunotherapy of malignant gliomas in the context of EGFR expression in grade III and IV tumors. Hybridoma (Larchmt) 2006;25(3):125-32

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.